Oncology
2 drugs are in development for Metastatic Pancreatic Cancer.
- Companies
- 2
- Clinical trials
- 19
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Pancreatic Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| ivospemin | PANBELA THERAPEUTICS, INC. (SNBP) |
Unknown(1)
| Drug | Company |
|---|---|
| sm-88 | TYME TECHNOLOGIES, INC. (TYME) |
About this indication
Metastatic Pancreatic Cancer context
Oncology·MeSH: Pancreatic Neoplasms (D010190)
Narrower concept of MeSH descriptor Pancreatic Neoplasms
Prevalence
8.0 / 100K
Incidence
13.1 / 100K/yr
Frequently asked questions
How many drugs are in development for Metastatic Pancreatic Cancer?
BioSniper tracks 2 drugs in development for Metastatic Pancreatic Cancer across 2 companies.
How many clinical trials target Metastatic Pancreatic Cancer?
There are 19 clinical trials targeting Metastatic Pancreatic Cancer tracked by BioSniper.
What is the prevalence of Metastatic Pancreatic Cancer?
The estimated prevalence of Metastatic Pancreatic Cancer is approximately 8.0 per 100,000 population.